PREVIOUS
✖
GLP-1 Drugs for Obesity
December 10 , 2025
15 hrs 0 min
6
0
- The WHO released global guidelines endorsing GLP-1 therapies for long-term treatment of obesity in adults, excluding pregnant women.
- GLP-1 therapies should be combined with diet and exercise interventions; medication alone is not sufficient to address obesity.
- The WHO issued a conditional recommendation due to limited long-term data on efficacy, safety, and outcomes after discontinuation, as well as high costs.
- Obesity contributes to major noncommunicable diseases and global economic costs, projected to reach $3 trillion annually by 2030.
- The WHO has emphasized equitable access to these drugs, calling for affordable generics, insurance coverage, and integrated obesity management systems worldwide.
Leave a Reply
Your Comment is awaiting moderation.